News

A mutation-agnostic gene therapy approach offers new possibilities for patients with advanced retinal disease.

The report highlights clinical successes, innovation, research, and patient outcomes.

A study reveals significant retinal vessel changes in diabetic retinopathy, highlighting the need for early detection methods to prevent vision loss.

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium

Anat Loewenstein, MD, presented real-world results of remote imaging at the International SPECTRALIS Symposium

Catch up on this week's highlights in retina.

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.

Dr Brunstetter, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, delivered the lecture at this year's ISS alongside his colleague Warren Hoburg

The rationale for the study under discussion is that the experience level of the operating surgeon is a potential factor affecting the outcomes of all ophthalmic procedures, including ISBCS

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

Prof Malik shared his presentation, titled "An eye on neurodegenerative diseases: Challenging the dogma," at this year's International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

Amneal Pharmaceuticals received FDA approval for its prednisolone acetate ophthalmic suspension, a steroid eye inflammation treatment referencing Allergan’s Pred Forte, with a US launch planned for Q3 2025.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

Harrow expects BYQLOVI to be commercially available in the fourth quarter of 2025.

The novel preservative-free eye drop therapy for glaucoma aims to improve IOP control and patient adherence with a fixed-dose combination.

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.